Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Cameron J Turtle,Elizabeth Budde,Krina K Patel,Miguel-Angel Perales,Andrew J Cowan,Hayder Saeed,Julio C Chavez,Alexandre V Hirayama,Delaney R Kirchmeier,Murali Janakiram,Kai Wu,Lawrence Fong,Zachary Lee,Neha Dixit,Xiaoli Wang,Kazuharu Kai,Mario Q Marcondes,Jonathan Zalevsky,Nina Shah

doi:10.1182/blood-2021-147350

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Cameron J Turtle, Elizabeth Budde + Show 17 more

Open Access

https://doi.org/10.1182/blood-2021-147350

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 4

Affiliation: Fred Hutch Cancer Center, University of Washington, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, University of Minnesota, University of California, San Francisco, Nektar Therapeutics (United States)

#Privately-held Company #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.